Special Issue "Advances in Respiratory Allergies"

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".

Deadline for manuscript submissions: 31 December 2023 | Viewed by 1629

Special Issue Editor

1. Respiratory and Allergy Clinic, Department of Internal Medicine (DIMI), University of Genoa, 16132 Genoa, Italy
2. IRCCS Policlinico San Martino, 16132 Genoa, Italy
Interests: asthma; severe asthma; lung disease; lung physiopathology; T2 inflammation; rhinosinusitis; nasal polyps

Special Issue Information

Dear Colleagues,

In recent decades, increasing knowledge of disease mechanisms has made it possible to address allergic diseases of the respiratory tract more effectively.

An enhanced understanding of type 2 inflammation has led to the use of biologic drugs for the treatment of asthma and rhino-sinus pathologies, which at first only acted on IgE, but now act on interleukin (IL) 5 or its receptor at the IL-4 receptor; in the near future, targeting alarmins with anti-TSLP is expected.

Therapeutic approaches with biologic drugs, in the context of allergic diseases of the respiratory tract, are also associated with allergen-specific immunotherapy, which has long been known to be an important cornerstone in the treatment of the allergic patient.

This Special Issue aims to present a collection of papers detailing both the history of allergy therapy in the respiratory tract field and the most recent innovations in the therapeutic field. Special interest will be paid to biological therapies, action on respiratory allergies, action of drugs on both nasal and bronchial districts, and allergen-specific immunotherapy as a therapy and modifying factor in the natural history of the disease.

Dr. Diego Bagnasco
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • asthma
  • rhino-sinusitis with nasal polyps
  • rhinitis
  • allergen
  • immunotherapy
  • small airways
  • biologics
  • biomarkers
  • cytokines
  • new therapies
  • personalized and precision medicine

Published Papers (2 papers)

Order results
Result details
Select all
Export citation of selected articles as:

Research

13 pages, 698 KiB  
Communication
Managing Severe Adverse Reactions to Biologicals in Severe Asthma
Biomedicines 2023, 11(12), 3108; https://doi.org/10.3390/biomedicines11123108 - 21 Nov 2023
Viewed by 358
Abstract
Background: The use of biological agents in the treatment of various inflammatory and malignancy conditions has expanded rapidly. However, these agents can induce hypersensitivity reactions, posing significant clinical challenges. Methods: We conducted a retrospective study that included nine patients with severe asthma who [...] Read more.
Background: The use of biological agents in the treatment of various inflammatory and malignancy conditions has expanded rapidly. However, these agents can induce hypersensitivity reactions, posing significant clinical challenges. Methods: We conducted a retrospective study that included nine patients with severe asthma who experienced hypersensitivity reactions to biological agents (omalizumab, benralizumab and dupilumab). Results: Hypersensitivity reactions to biologicals in severe asthma were observed in 9 of 68 patients treated. In five cases, treatment was stopped or changed to another available biological, and for four patients administered under close surveillance, titrated provocation or desensitization was applied. Successful desensitization was achieved in three of the patients, allowing them to continue therapy without adverse reactions. Improvements in asthma control were observed post-desensitization, leading to the reduced need for systemic steroid treatments and an increase in quality of life. Conclusions: This study highlights the importance of recognizing hypersensitivity reactions to biologicals to have an appropriate approach for patients with severe asthma. As an effective approach for patients experiencing hypersensitivity reactions to biological agents, desensitization allows treatment continuation. Full article
(This article belongs to the Special Issue Advances in Respiratory Allergies)
Show Figures

Figure 1

10 pages, 954 KiB  
Article
Long-Term Efficacy of Mepolizumab at 3 Years in Patients with Severe Asthma: Comparison with Clinical Trials and Super Responders
Biomedicines 2023, 11(9), 2424; https://doi.org/10.3390/biomedicines11092424 - 30 Aug 2023
Cited by 1 | Viewed by 777
Abstract
The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. [...] Read more.
The efficacy mepolizumab in severe asthmatic patients is proven in the literature. Primarily to study the effect of mepolizumab on exacerbations, steroid dependence, and the continuation of efficacy in the long term. Secondarily to evaluate the effect of the drug on nasal polyps. Analyzing data from SANI (Severe Asthma Network Italy) clinics, we observed severe asthmatic patients treated with mepolizumab 100 mg/4 weeks, for a period of 3 years. 157 patients were observed. Exacerbations were reduced from the first year (−84.6%) and progressively to 90 and 95% in the second and third ones. Steroid-dependent patients decreased from 54% to 21% and subsequently to 11% in the second year and 6% in the third year. Patients with concomitant nasal polyps, assessed by SNOT-22, showed a 49% reduction in value from baseline to the third year. The study demonstrated the long-term efficacy of mepolizumab in a real-life setting. Full article
(This article belongs to the Special Issue Advances in Respiratory Allergies)
Show Figures

Figure 1

Back to TopTop